ArticleCroatian medical journal2025
Adherence to denosumab therapy and fracture risk associated with drug withdrawal: a retrospective study.
Article in Croatian medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo assess the prevalence of fragility fractures after denosumab discontinuation and to identify the factors affecting treatment adherence.
methodsWe retrospectively reviewed the medical records of 3876 osteoporosis patients who were treated with denosumab at Trakya University Osteoporosis Clinic between 2015 and 2021. A total of 210 patients who received at least two regular doses of denosumab were eligible for inclusion. Patients were categorized as denosumab-adherent and denosumab-non-adherent. Adherence was defined as receiving the six-month scheduled dose with a maximum delay of up to eight weeks.
resultsOverall, 124 (59.05%) patients were denosumab-adherent and 86 patients (40.95%) were denosumab-non-adherent. New fragility fractures were identified in 32 patients: 17 in the denosumab-adherent group and 15 in the denosumab-non-adherent group. The groups did not significantly differ in the risk or types of new fractures, irrespective of patients' fracture history.
conclusionsOur findings suggest that some fractures after denosumab discontinuation may stem from the natural progression of osteoporosis rather than from the rebound effect. Still, unscheduled treatment discontinuation should be prevented.
Indexed as
Identifiers
41200943PMC12623255What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.